Stokes Family Office LLC Sells 2,033 Shares of Pfizer Inc. (NYSE:PFE)

Stokes Family Office LLC trimmed its stake in shares of Pfizer Inc. (NYSE:PFE) by 2.7% during the first quarter, HoldingsChannel.com reports. The firm owned 73,225 shares of the biopharmaceutical company’s stock after selling 2,033 shares during the quarter. Stokes Family Office LLC’s holdings in Pfizer were worth $2,032,000 as of its most recent filing with the SEC.

A number of other institutional investors have also added to or reduced their stakes in PFE. GoalVest Advisory LLC lifted its holdings in shares of Pfizer by 304.9% in the fourth quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 811 shares in the last quarter. Creekmur Asset Management LLC purchased a new stake in Pfizer in the 4th quarter worth approximately $32,000. Trivant Custom Portfolio Group LLC boosted its holdings in Pfizer by 100.0% in the 1st quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 600 shares during the period. VisionPoint Advisory Group LLC increased its holdings in shares of Pfizer by 52,350.0% in the third quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 1,047 shares during the period. Finally, Tennessee Valley Asset Management Partners purchased a new stake in shares of Pfizer in the fourth quarter worth $36,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Trading Up 0.9 %

PFE traded up $0.26 on Friday, hitting $28.92. 28,153,470 shares of the company were exchanged, compared to its average volume of 40,011,234. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.78 and a current ratio of 1.05. The firm has a fifty day simple moving average of $28.23 and a two-hundred day simple moving average of $27.72. The stock has a market capitalization of $163.88 billion, a PE ratio of -484.33, a price-to-earnings-growth ratio of 1.11 and a beta of 0.69. Pfizer Inc. has a 12 month low of $25.20 and a 12 month high of $37.80.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share for the quarter, beating analysts’ consensus estimates of $0.56 by $0.26. Pfizer had a positive return on equity of 8.64% and a negative net margin of 0.56%. The firm had revenue of $14.88 billion during the quarter, compared to analyst estimates of $13.87 billion. During the same quarter in the prior year, the firm posted $1.23 earnings per share. The business’s quarterly revenue was down 19.5% compared to the same quarter last year. Sell-side analysts expect that Pfizer Inc. will post 2.38 earnings per share for the current year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 3rd. Shareholders of record on Friday, July 26th will be given a $0.42 dividend. This represents a $1.68 dividend on an annualized basis and a dividend yield of 5.81%. The ex-dividend date is Friday, July 26th. Pfizer’s payout ratio is -2,800.00%.

Analyst Upgrades and Downgrades

PFE has been the topic of a number of research analyst reports. BMO Capital Markets restated an “outperform” rating and issued a $36.00 target price (up from $33.00) on shares of Pfizer in a research note on Thursday, May 2nd. Morgan Stanley upped their price objective on shares of Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a research report on Thursday, May 2nd. Barclays lifted their target price on shares of Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a research report on Wednesday. Argus lowered shares of Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a report on Wednesday. Nine research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat.com, Pfizer currently has a consensus rating of “Hold” and a consensus price target of $35.69.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.